| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 04/01/2004 | US20040062716 Aerosol; high speed absorption; mixture of solvent and active materials |
| 04/01/2004 | DE202004000330U1 Dermatological ointment, e.g. useful for treating dry skin, wounds, ulcers, nappy rash and sunburn, comprises pumpkin seed oil, soya oil, fluid lecithin and a flavoring oil |
| 04/01/2004 | DE10252929A1 Using sparingly soluble calcium salt for local remineralization of teeth, useful for treating sensitive teeth, also inhibits development of caries |
| 04/01/2004 | DE10244397A1 Cholinascorbat-Formulierungen Choline formulations |
| 04/01/2004 | DE10243126A1 Propellant mixture for pharmaceutical aerosols, containing 1,1,1,3,3-pentafluorobutane and/or 1,1,2,2,3,3-hexafluoropropane as co-propellant having pressure reducing and drug stabilizing action |
| 04/01/2004 | DE10212286A1 Effervescent tablet production, e.g. for medicinal, food or detergent applications, by forming premix of solid acid and liquid polyol, mixing with active agent and carbonate and directly pressing to tablets |
| 04/01/2004 | CA2499996A1 Triplex hairpin ribozyme |
| 04/01/2004 | CA2499900A1 Dri nasal sprays |
| 04/01/2004 | CA2499859A1 Vitreoretinal tamponades based on fluorosilicone fluids |
| 04/01/2004 | CA2499681A1 Drug delivery |
| 04/01/2004 | CA2499550A1 Sequestering subunit and related compositions and methods |
| 04/01/2004 | CA2499472A1 Non gelatin films with improved barrier properties |
| 04/01/2004 | CA2499149A1 Mannitol formulation for integrin receptor antagonist |
| 04/01/2004 | CA2499093A1 Pharmaceutical composition for topical delivery of meloxicam comprising an amine or amine as penetration enhancer. |
| 04/01/2004 | CA2498890A1 Modified release formulations of oxcarbazepine and derivatives thereof |
| 04/01/2004 | CA2498331A1 Formulation for lipophilic agents |
| 04/01/2004 | CA2497878A1 Improvements in or relating to vaccines |
| 04/01/2004 | CA2496332A1 Oral formulations |
| 03/31/2004 | EP1403284A1 HAb18G/CD147, IT'S AGONIST AND APPLICATION |
| 03/31/2004 | EP1402913A1 Dry powder inhalation system for transpulmonary administration |
| 03/31/2004 | EP1402906A1 Synechia inhibitory material |
| 03/31/2004 | EP1402897A2 Novel indications of Mannan-binding lectin (MBL) in the treatment of immunocompromised individuals |
| 03/31/2004 | EP1402884A1 Liposome-containing remedy for the treatment of vascular diseases |
| 03/31/2004 | EP1402882A1 Acid-containing tooth desensitising material |
| 03/31/2004 | EP1402786A1 Ximenynic acid |
| 03/31/2004 | EP1401918A2 Biodegradable poly(beta-amino esters) and uses thereof |
| 03/31/2004 | EP1401838A2 Novel substituted tetracyclic imidazole derivatives, processes for their preparation, pharmaceutical compositions comprising them and their use as a medicine |
| 03/31/2004 | EP1401818A2 Targeted multivalent macromolecules |
| 03/31/2004 | EP1401567A1 Unimolecular polymeric micelles with an ionizable inner core |
| 03/31/2004 | EP1401563A1 Process for the production of micro and/or nano particles |
| 03/31/2004 | EP1401551A1 Nanoparticle structures |
| 03/31/2004 | EP1401503A1 Pharmaceutical compositions containing a solid dispersion of a poorly-soluble drug in a matrix and a solubility-enhancing polymer |
| 03/31/2004 | EP1401502A1 Pharmaceutical formulation |
| 03/31/2004 | EP1401501A1 Oral pharmaceutical compositions with modified release of the active ingredient |
| 03/31/2004 | EP1401500A1 Nucleotide compounds that block the bitter taste of oral compositions |
| 03/31/2004 | EP1401480A2 Use of endostatin in the treatment of ocular neovascularization |
| 03/31/2004 | EP1401479A2 Detection and therapy of vulnerable plaque with photodynamic compounds |
| 03/31/2004 | EP1401472A2 Alternative splice forms of proteins as basis for multiple therapeutic modalities |
| 03/31/2004 | EP1401466A1 Agent containing fat (oil), which contains onion extract, the production and use thereof for caring, preventing or treating damaged skin tissue, especially scarred tissue |
| 03/31/2004 | EP1401458A2 Composition consisting of phy906 and chemotherapeutic agents |
| 03/31/2004 | EP1401445A1 Crystalline anticholinergic, method for its production, and use thereof in the production of a drug |
| 03/31/2004 | EP1401437A1 Immune response modifiers for the treatment of periodontal disease |
| 03/31/2004 | EP1401435A1 Topical application of thiazolyl amides |
| 03/31/2004 | EP1401423A1 Method of treating gastroesophageal reflux disease and nocturnal acid breakthrough |
| 03/31/2004 | EP1401418A2 Topical treatments using alkanolamines |
| 03/31/2004 | EP1401409A2 Stable powder inhalation dosage formulation |
| 03/31/2004 | EP1401408A1 Controlled heat induced rapid delivery of pharmaceuticals from skin depot |
| 03/31/2004 | EP1401406A2 Delivery of a bioactive material |
| 03/31/2004 | EP1401405A1 Oral pharmaceutical compositions with improved bioavailability |
| 03/31/2004 | EP1401404A2 Method of encapsulating an active substance |
| 03/31/2004 | EP1401403A2 Medicinal compositions comprising a melting core encapsulated in a hydroxypropylmethylcellulose film |
| 03/31/2004 | EP1401402A2 Enhancement of oral bioavailability of non-emulsified formulation of prodrug esters with lecithin |
| 03/31/2004 | EP1401401A2 Method for high through put screening using a small scale mill or microfluidics |
| 03/31/2004 | EP1401400A1 Porous matrix comprising cross-linked particles |
| 03/31/2004 | EP1401399A2 Pharmaceutical compositions containing polymer and drug assemblies |
| 03/31/2004 | EP1401398A1 PHARMACEUTICAL FORMULATION FOR THE EFFICIENT ADMINISTRATION OF APOMORPHINE, 6aR-(-)-N-PROPYL-NORAPOMORPHINE AND THEIR DERIVATIVES AND PRO-DRUGS THEREOF |
| 03/31/2004 | EP1401397A2 Pharmaceutical formulation having a masked taste and method for the production thereof |
| 03/31/2004 | EP1401396A2 Pharmaceutical and diagnostic compositions containing nanoparticles useful for treating targeted tissues and cells |
| 03/31/2004 | EP1401395A1 Osmotic implant with membrane and membrane retention means |
| 03/31/2004 | EP1401376A2 Colloidal metal compositions and methods |
| 03/31/2004 | EP1401294A1 Method for manufacturing of free-flowing powder containing water-dispersible sterols |
| 03/31/2004 | EP1401293A1 Calorically dense liquid oral supplement |
| 03/31/2004 | EP1401290A2 Composition for regulating animal growth, method of manufacture and use thereof |
| 03/31/2004 | EP1401275A1 Antiviral composition and treatment method |
| 03/31/2004 | EP1305010B1 Dosage forms for treatment of oral mycoses |
| 03/31/2004 | EP1294742B1 Urokinase inhibitors |
| 03/31/2004 | EP1230338A4 Continuous-flow method for preparing microparticles |
| 03/31/2004 | EP1220685B1 Pharmaceutical compositions of fibrinolytic agent |
| 03/31/2004 | EP1218026B1 Preparation of a medicament to enhance healing of the sternum after sternotomy |
| 03/31/2004 | EP1210072B1 Plastic films, especially for use in a dermal or transdermal therapeutic system |
| 03/31/2004 | EP1171132B1 Injectable naltrexone microsphere compositions and their use in reducing consumption of heroin and alcohol |
| 03/31/2004 | EP1165053B1 Fast-dispersing dosage forms containing fish gelatin |
| 03/31/2004 | EP1126851B1 Pharmaceutical formulations in hydroxypropylmethylcellulose capsules |
| 03/31/2004 | EP1124543A4 Controlled release formulation for water soluble drugs |
| 03/31/2004 | EP1109526B1 Improved stability for injection solutions |
| 03/31/2004 | EP1073438B1 8-CHLORO-6,11-DIHYDRO-11-(4-PIPERIDYLIDINE)-5H-BENZO (5,6) CYCLOHEPTA (1,2-b) PYRIDINE ORAL COMPOSITIONS |
| 03/31/2004 | EP1062032B1 Method and device for capsulating microbial, plant and animal cells or biological and chemical substances |
| 03/31/2004 | EP1053020B1 Absorbable microparticles |
| 03/31/2004 | EP1051451B1 An article having a surface showing adhesive properties |
| 03/31/2004 | EP0996431B1 Synergistic compositions of lycopene and vitamin e for the prevention of ldl oxidation |
| 03/31/2004 | EP0988028B1 Use of a composition comprising capsaicin or resiniferatoxin for the treatment of Irritable Bowel Syndrome |
| 03/31/2004 | EP0975367B1 Improved delivery of drugs to mucosal surfaces |
| 03/31/2004 | EP0929229B2 Chewing gum with sweetening agent |
| 03/31/2004 | EP0914070B1 Dental floss with increased loading weight |
| 03/31/2004 | EP0873130B1 Compositions comprising pvp having an average molecular weight in the range of 7.000 to 12.000 daltons |
| 03/31/2004 | EP0871758B1 Liposomal transfection method |
| 03/31/2004 | EP0858323B1 Process to manufacture implants containing leuprolide |
| 03/31/2004 | EP0809498B1 Pharmaceuitical composition for topical application containing acyclovir and hydrocortisone |
| 03/31/2004 | EP0781766B1 Heterocyclic derivative and medicine |
| 03/31/2004 | EP0777484B1 Intravenous alendronate formulations |
| 03/31/2004 | EP0772445B1 Pharmaceutical compositions, mainly vaginal suppository, containing many different active ingredients |
| 03/31/2004 | EP0744951B1 Process for producing a sterile prednisolone gel |
| 03/31/2004 | CN2608003Y Medical magnetic acupoint plaster |
| 03/31/2004 | CN1486313A Compounds for use in the treatment of skin conditions |
| 03/31/2004 | CN1486196A Complex of modafinil and cyclodextrin |
| 03/31/2004 | CN1486188A Improved ophthalmic and contact lens solutions containing simple saccharides as preservative enhancers |
| 03/31/2004 | CN1486187A L-histidine in ophthalmic solutions |
| 03/31/2004 | CN1486186A Improved ophthalmic and contact lens solutions containing forms of vitamin B |
| 03/31/2004 | CN1486185A Stabilized brivudine topical formulations containing metal oxide pigments |
| 03/31/2004 | CN1486183A Treatment of anti-depression drug-induced sexual dysfunction with apomorphine |